572-573 / 1708
Non-infants (PNET5-MB and HR-MB):
Next biology steps
•
Next biomarkers / refine risk-
stratification:
•
New subgroups
•
Level of evidence?
•
When?
•
New strategies for VHR patients
•
Identify targeted therapeutics:
•
Link to pre-clinical / early-phase initiatives
•
HR-MB window